Thomas Schinecker

Thomas Schinecker is an Austrian business executive who has served as the chief executive officer of the global healthcare company Roche since March 2023. He succeeded long-time CEO Severin Schwan after a distinguished career within the Basel-based corporation, primarily leading its diagnostics division. Schinecker's appointment marked a significant leadership transition for one of the world's largest pharmaceutical and diagnostics enterprises, with a focus on navigating the post-pandemic landscape and advancing personalized healthcare.

Early life and education

Thomas Schinecker was born in Austria and pursued his higher education in his home country. He earned a doctorate in genetics and microbiology from the University of Vienna, where his academic research laid a foundational understanding of life sciences. His doctoral work contributed to the scientific community's knowledge in molecular biology, a field directly relevant to the future of biotechnology and pharmaceutical research. Following his studies, he began his professional journey, which would quickly align with the healthcare industry.

Career at Roche

Schinecker joined Roche in 2003 within the Roche Diagnostics division, starting in a marketing role for the PCR and nucleic acid purification business. He rapidly ascended through various leadership positions, demonstrating expertise in the in-vitro diagnostics market. Key roles included heading the Central Europe region for Roche Diagnostics and later serving as the global head of the Professional Diagnostics business area. His leadership was instrumental in expanding Roche's diagnostics portfolio, including critical tests in areas like cardiology, oncology, and infectious diseases. In 2019, he was appointed CEO of Roche Diagnostics, overseeing the division's global strategy and operations during the pivotal period of the COVID-19 pandemic, where the unit's rapid development and rollout of SARS-CoV-2 tests were crucial to the global response.

Leadership and tenure as CEO

Upon becoming Group CEO of Roche in March 2023, Schinecker assumed responsibility for the entire corporation's portfolio, encompassing the Pharmaceuticals Division and the Diagnostics Division. His early tenure has focused on strengthening Roche's research and development pipeline, particularly in oncology, neuroscience, and immunology, while integrating diagnostics and pharmaceuticals to advance personalized medicine. Strategic priorities include navigating patent expirations for key drugs like Ocrevus and Hemlibra, investing in next-generation modalities such as bispecific antibodies and radiopharmaceuticals, and managing the post-pandemic market normalization for COVID-19-related products. He also chairs the Corporate Executive Committee of Roche, steering the company's response to evolving healthcare regulations, competitive pressures from firms like Novartis and Pfizer, and the growing importance of artificial intelligence in drug discovery.

Other professional activities

Beyond his executive duties at Roche, Schinecker serves on several boards and industry bodies that influence global health policy and innovation. He is a member of the Board of Directors of the European Federation of Pharmaceutical Industries and Associations (EFPIA), advocating for the pharmaceutical industry in Europe. His insights are frequently sought at major international forums such as the World Economic Forum in Davos and the JP Morgan Healthcare Conference. Schinecker also contributes to academic and scientific advisory boards, helping to shape the future of biomedical research and its translation into clinical practice.

Personal life

Thomas Schinecker maintains a relatively private personal life. He is married and has children. A citizen of Austria, he resides with his family in Switzerland due to his professional commitments at Roche's headquarters in Basel. He is known to be an avid skier, enjoying the Alpine regions of both his home country and his adopted nation. Colleagues describe his leadership style as analytical and decisive, shaped by his deep scientific background and extensive commercial experience in the global healthcare market.

Category:Austrian businesspeople Category:Chief executive officers Category:Roche people Category:University of Vienna alumni